Most common side effects are diarrhea, nausea, abdominal pain, and vomiting. Fewer than 1% of patients stop taking the drug due to side effects. Nervousness, dermatologic reactions, and anaphylaxis have been reported. As with all antimicrobial agents, pseudomembranous colitis can occur during and up to several weeks after azithromycin therapy. In the past, physicians cautioned women that antibiotics can reduce the effectiveness of oral contraceptives.

With the AZITHROMYCIN Discount Card, all patients are eligible to:

  • Save up to 80% off out-of-pocket costs*
  • Pay as little as $14 each month for your 6-ct prescription**
  • Reuse this coupon card – it never expires
Print Your Pre-activated Discount Card Today!
Show the pharmacist this card from your phone or tablet.
AZITHROMYCIN Prescription Discount Card

*Offer Details:

  • This Discount Card is not health insurance and cannot be used to lower your co-pay. The discount card price may be lower than your health insurance co-pay. Ask your pharmacist to help you find the best possible price.
  • This coupon card cannot be used in conjunction with any federal or state funded program, such as medicare or medicaid.
  • Card is accepted at over 68,000 participating pharmacies, may be used an unlimited number of times, and provides discounts on most medication.

To the Patient:

  • Simply print your AZITHROMYCIN Discount Card, it works like a coupon.
  • Present your AZITHROMYCIN Discount Card with your prescription to your pharmacy and you may pay less on your prescriptions.
  • On each 6-ct supply, your Discount Card may deduct from your out-of-pocket costs up to $59.**
  • Make sure to keep this Discount Card—do not leave it with the pharmacy. You will need to show your Discount Card for every prescription refill to get the savings.

To the Pharmacist:

Please use the card's BIN, PCN and Group number to adjudicate. For questions, please call 1-800-223-2146.

**Example savings are based on discounts from a prescription of AZITHROMYCIN 250mg Tablet. Prices vary by pharmacy and prescription and are subject to change over time. Ask your pharmacist for the actual discounted price.

Save on your AZITHROMYCIN Prescription Costs

The AZITHROMYCIN Discount Card was designed to help make AZITHROMYCIN prescriptions more affordable for patients. Below are some examples of actual savings. Ask your pharmacist for your discount price.

Prescription Quantity Retail Price Discounted Price Savings
AZITHROMYCIN 250mg Tablet6$72.79$14.1280.60%
AZITHROMYCIN 500mg Tablet2$60.99$14.7875.77%
AZITHROMYCIN 600mg Tablet8$171.88$61.6664.13%
AZITHROMYCIN 100mg/5ml Bottle of Oral Suspension15$78.49$30.8260.73%
AZITHROMYCIN 200mg/5ml Bottle of Oral Suspension15$80.99$16.1880.02%
AZITHROMYCIN 1gm Packet1$76.49$16.6078.30%
  • AZITHROMYCIN 250mg Tablet
  • Retail Price for 6 Tablets: $72.79
  • With Discount Card: $14.12
  • Save 80.60%
  • AZITHROMYCIN 200mg/5ml Suspension
  • Retail Price for 15: $80.99
  • With Discount Card: $16.18
  • Save 80.02%
  • AZITHROMYCIN 1gm Packet
  • Retail Price for 1 Packet: $76.49
  • With Discount Card: $16.60
  • Save 78.30%
  • AZITHROMYCIN 500mg Tablet
  • Retail Price for 2 Tablets: $60.99
  • With Discount Card: $14.78
  • Save 75.77%



    To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZITHROMYCIN and other antibacterial drugs, AZITHROMYCIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

    AZITHROMYCIN is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.

    Adult Patients

    • Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae.
    • Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae.
    • Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy.
    • Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy.
    • Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes , or Streptococcus agalactiae.
    • Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae.
    • Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of AZITHROMYCIN in the treatment of chancroid in women has not been established.

    Pediatric Patients

    • Acute otitis media ( >6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis , or Streptococcus pneumoniae
    • Community-acquired pneumonia ( >6 months of age) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy.
    • Pharyngitis/tonsillitis ( >2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy.

    Limitations of Use

    AZITHROMYCIN should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:

    • patients with cystic fibrosis,
    • patients with nosocomial infections,
    • patients with known or suspected bacteremia,
    • patients requiring hospitalization,
    • elderly or debilitated patients, or
    • patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia).


    AZITHROMYCIN tablets are contraindicated in patients with known hypersensitivity to AZITHROMYCIN, erythromycin, any macrolide or ketolide drug.

    Hepatic Dysfunction

    AZITHROMYCIN tablets are contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of AZITHROMYCIN.


    Sexually Transmitted Diseases

    The recommended dose of AZITHROMYCIN for the treatment of non-gonococcal urethritis and cervicitis due to C. trachomatis is a single 1000 mg dose of AZITHROMYCIN.

    Mycobacterial Infections

    Prevention of Disseminated MAC Infections

    The recommended dose of AZITHROMYCIN for the prevention of disseminated Mycobacterium avium complex (MAC) disease is: 1200 mg taken once weekly. This dose of AZITHROMYCIN may be combined with the approved dosage regimen of rifabutin.

    Treatment of Disseminated MAC Infections

    AZITHROMYCIN should be taken at a daily dose of 600 mg, in combination with ethambutol at the recommended daily dose of 15 mg/kg. Other antimycobacterial drugs that have shown in vitro activity against MAC may be added to the regimen of AZITHROMYCIN plus ethambutol at the discretion of the physician or health care provider.


    AZITHROMYCIN tablets, USP, equivalent to 250 mg AZITHROMYCIN, are white, oval-shaped, unscored, film-coated tablets, debossed GG D6 on one side and plain on the reverse side, and are supplied as follows:

    • in bottles of 30 tablets
    • in bottles of 100 tablets
    • Unit Dose Package of 50 tablets
    • Package of 18 tablets (3 x 6 unit-of-use blisters)

    AZITHROMYCIN tablets, USP, equivalent to 500 mg AZITHROMYCIN, are white, oval-shaped, unscored, film-coated tablets, debossed GG D8 on one side and plain on the reverse side, and are supplied as follows:

    • in bottles of 30 tablets
    • in bottles of 100 tablets
    • Package of 9 tablets (3 x 3 unit-of-use blisters)

    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

    Dispense in a tight container


Frequently Asked Questions

  • How does the AZITHROMYCIN Prescription Discount Card work? is partnered with companies that negotiate discounts directly with the pharmacies. These discounts are then passed directly on to cardholders.

  • Who is eligible for the AZITHROMYCIN Prescription Discount Card?

    The AZITHROMYCIN Prescription Discount Card has no requirements. Unlike insurance programs, there is no income, age, pre-existing condition, deductible, or waiting period restrictions. The free discount card is designed to help patients nationwide who do not have prescription drug coverage or who have coverage but are subject to large deductibles, large co-pays, formulary limitations, dosing limitations, gaps, and/or any cash out-of-pocket expenses.

  • How much does the AZITHROMYCIN Prescription Discount Card/Coupon cost?

    The AZITHROMYCIN Prescription Discount Card is absolutely FREE. We provide this service to every American that wishes to save on their AZITHROMYCIN prescription cost. There are no premiums or deductibles associated with this program whatsoever. The printable card/coupon is available free of charge from our website.

  • How do I use the AZITHROMYCIN Prescription Discount Card?
    1. Select a pharmacy: the AZITHROMYCIN Prescription Discount Card is valid at over 68,000 network pharmacy locations nationwide. In most cases, your current pharmacy will be part of our network.
    2. Submit your prescription: Present your AZITHROMYCIN prescription to the pharmacist. If you need to transfer a prescription, bring your empty prescription bottle or label with you to the pharmacy.
    3. Present your AZITHROMYCIN Prescription Discount Card: Your card's unique code provides the pharmacist with the appropriately discounted prescription price. The price on the prescription is based on the pharmacy's contracted agreement with and our partners.
    4. You Save: Your savings will be clear once the pharmacist enters your filled prescription into the register. Whether the lowest discount price is the AZITHROMYCIN Prescription Discount Card price, your present insurance program's price, or the pharmacy's already discounted price, you are GUARANTEED to receive the LOWEST price available!
  • Which pharmacies can I go to?

    We have a constantly expanding list of over 68,000 participating major chain pharmacies and local pharmacies nationwide including CVS/Pharmacy, Walgreens, Target Pharmacy, Walmart Pharmacy, Safeway, Rite Aid, and more!

  • How can I be assured I am getting the lowest price?

    The discounted price may vary by as much as 75% depending on the pharmacy discount rate contracted with While pharmacy prices may vary from week-to-week and by the geographic location, the patient is guaranteed the lowest price available regardless of whether it is the price, your present insurance program's price, or the pharmacy's already discounted price.

AZITHROMYCIN Safety Information



    Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in patients on AZITHROMYCIN therapy.

    Fatalities have been reported. Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further AZITHROMYCIN exposure. These patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of AZITHROMYCIN and subsequent prolonged exposure to antigen is presently unknown.

    If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that allergic symptoms may reappear when symptomatic therapy has been discontinued.


    Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death. Discontinue AZITHROMYCIN immediately if signs and symptoms of hepatitis occur.

    QT Prolongation

    Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen with treatment with macrolides, including AZITHROMYCIN. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving AZITHROMYCIN. Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of AZITHROMYCIN for at-risk groups including:

    • patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure
    • patients on drugs known to prolong the QT interval
    • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
    • Elderly patients may be more susceptible to drug-associated effects on the QT interval.

    Clostridium difficile-Associated Diarrhea (CDAD)

    Clostridium difficile-associated diarrhea has been reported with use of nearly all antibacterial agents, including AZITHROMYCIN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile.

    C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

    If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

    Exacerbation of Myasthenia Gravis

    Exacerbation of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving AZITHROMYCIN therapy.

    Use in Sexually Transmitted Infections

    AZITHROMYCIN, at the recommended dose, should not be relied upon to treat syphilis. Antibacterial agents used to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate testing for gonorrhea performed at the time of diagnosis. Appropriate antibacterial therapy and follow-up tests for these diseases should be initiated if infection is confirmed.

    Development of Drug-Resistant Bacteria

    Prescribing AZITHROMYCIN in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.


    AZITHROMYCIN tablets may be taken with or without food. However, increased tolerability has been observed when tablets are taken with food.

    Patients should also be cautioned not to take aluminum-and magnesium-containing antacids and AZITHROMYCIN simultaneously.

    The patient should be directed to discontinue AZITHROMYCIN immediately and contact a physician if any signs of an allergic reaction occur.

    Patients should be counseled that antibacterial drugs, including AZITHROMYCIN, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When AZITHROMYCIN is prescribed to treat bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by AZITHROMYCIN or other antibacterial drugs in the future.

    Diarrhea is a common problem caused by antibacterial which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should contact their physician as soon as possible.


    Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    In clinical trials, most of the reported adverse reactions were mild to moderate in severity and were reversible upon discontinuation of the drug. Approximately 0.7% of the patients from the multiple-dose clinical trials discontinued AZITHROMYCIN therapy because of treatment-related adverse reactions. Serious adverse reactions included angioedema and cholestatic jaundice. Most of the adverse reactions leading to discontinuation were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain.

    Multiple-dose regimen

    Overall, the most common adverse reactions in adult patients receiving a multiple-dose regimen of AZITHROMYCIN were related to the gastrointestinal system with diarrhea/loose stools (5%), nausea (3%), and abdominal pain (3%) being the most frequently reported.

    No other adverse reactions occurred in patients on the multiple-dose regimen of AZITHROMYCIN with a frequency greater than 1%. Adverse reactions that occurred with a frequency of 1% or less included the following:

    • Cardiovascular: Palpitations and chest pain.
    • Gastrointestinal: Dyspepsia, flatulence, vomiting, melena, and cholestatic jaundice.
    • Genitourinary: Monilia, vaginitis, and nephritis.
    • Nervous System: Dizziness, headache, vertigo, and somnolence.
    • General: Fatigue.
    • Allergic: Rash, photosensitivity, and angioedema.

    Chronic therapy with 1200 mg weekly regimen

    The nature of adverse reactions seen with the 1200 mg weekly dosing regimen for the prevention of Mycobacterium avium infection in severely immunocompromised HIV-infected patients were similar to those seen with short-term dosing regimens.

    Chronic therapy with 600 mg daily regimen combined with ethambutol

    The nature of adverse reactions seen with the 600 mg daily dosing regimen for the treatment of Mycobacterium avium complex infection in severely immunocompromised HIV-infected patients were similar to those seen with short term dosing regimens. Five percent of patients experienced reversible hearing impairment in the pivotal clinical trial for the treatment of disseminated MAC in patients with AIDS. Hearing impairment has been reported with macrolide antibiotics, especially at higher doses. Other treatment-related adverse reactions occurring in >5% of subjects and seen at any time during a median of 87.5 days of therapy include: abdominal pain (14%), nausea (14%), vomiting (13%), diarrhea (12%), flatulence (5%), headache (5%), and abnormal vision (5%). Discontinuations from treatment due to laboratory abnormalities or adverse reactions considered related to study drug occurred in 8 of 88 (9.1%) of subjects.

    Post-marketing Experience

    The following adverse reactions have been identified during post approval use of AZITHROMYCIN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Adverse reactions reported with AZITHROMYCIN during the postmarketing period in adult and/or pediatric patients for which a causal relationship may not be established include:

    • Allergic: Arthralgia, edema, urticaria, and angioedema.
    • Cardiovascular: Arrhythmias, including ventricular tachycardia, and hypotension. There have been reports of QT prolongation and torsades de pointes.
    • Gastrointestinal: Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea pseudomembranous colitis, pancreatitis, oral candidiasis, pyloric stenosis, and tongue discoloration.
    • General: Asthenia, paresthesia, fatigue, malaise, and anaphylaxis
    • Genitourinary: Interstitial nephritis, acute renal failure, and vaginitis.
    • Hematopoietic: Thrombocytopenia.
    • Liver/Biliary: Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure.
    • Nervous System: Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity, nervousness, agitation, and syncope.
    • Psychiatric: Aggressive reaction and anxiety.
    • Skin/Appendages: Pruritus, and serious skin reactions including erythema multiforme, Stevens -Johnson syndrome, and toxic epidermal necrolysis.
    • Special Senses: Hearing disturbances including hearing loss, deafness, and/or tinnitus, and reports of taste/smell perversion and/or loss.

    Laboratory Abnormalities

    Significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows:

    • With an incidence of 1 to 2%, elevated serum creatine phosphokinase, potassium, ALT (SGPT), GGT, and AST (SGOT).
    • With an incidence of less than 1%, leukopenia, neutropenia, decreased platelet count, elevated serum alkaline phosphatase, bilirubin, BUN, creatinine, blood glucose, LDH, and phosphate.
    • When follow-up was provided, changes in laboratory tests appeared to be reversible.

    In multiple-dose clinical trials involving more than 3000 patients, 3 patients discontinued therapy because of treatment-related liver enzyme abnormalities and 1 because of a renal function abnormality.

    In a phase 1 drug interaction study performed in normal volunteers, 1 of 6 subjects given the combination of AZITHROMYCIN and rifabutin, 1 of 7 given rifabutin alone, and 0 of 6 given AZITHROMYCIN alone developed a clinically significant neutropenia.

    Laboratory abnormalities seen in clinical trials for the prevention of disseminated Mycobacterium avium disease in severely immunocompromised HIV-infected patients.


    Adverse reactions experienced in higher than recommended doses were similar to those seen at normal doses. In the event of overdosage, general symptomatic and supportive measures are indicated as required.